retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial 40mg Retatrutide for Obesity: Phase 2
Description
But they do it through entirely different communication systems
Not optional
Meta-analyses have confirmed the benefit of GLP-1 RAs as a class in both secondary and primary prevention of cardiovascular disease, and in reduction of adverse kidney outcomes in people with T2D (Kristiensen et al, 2019
Although they may not be losing weight, their treatment may be controlling their blood glucose levels
Source: #GLP1 #MentalHealth #MetabolicHealth #Longevity #HealthLongevitySecrets Once someone loses the weight and wants to discontinue use, thats where a lot of the real questions begin
J Neurosci Res (2020) 98(11):235769
